These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3181009)

  • 1. Spironolactone: no longer for hypertension.
    Drug Ther Bull; 1988 Oct; 26(22):88. PubMed ID: 3181009
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of spironolactone in hypertensive patients.
    Crane MG; Harris JJ
    Am J Med Sci; 1970 Dec; 260(6):311-30. PubMed ID: 5511395
    [No Abstract]   [Full Text] [Related]  

  • 3. [Spironolactone is the best option in "resistant" hypertension].
    Overbeck P
    MMW Fortschr Med; 2015 Sep; 157(16):9. PubMed ID: 26783595
    [No Abstract]   [Full Text] [Related]  

  • 4. Spiroprop (spironolactone + propranolol) for hypertension.
    Drug Ther Bull; 1985 Apr; 23(8):31-2. PubMed ID: 3996214
    [No Abstract]   [Full Text] [Related]  

  • 5. Spironolactone for the treatment of isolated systolic hypertension.
    Yarows SA
    Am J Hypertens; 2004 Mar; 17(3):284. PubMed ID: 15001208
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone in resistant hypertension.
    Feely J; Mahmud A
    Hypertension; 2007 Sep; 50(3):e57; author reply e58. PubMed ID: 17606857
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of a spironolactone and althiazide combination (aldactacine) in Africans with benign essential hypertension.
    Pinto JM
    East Afr Med J; 1981 Jan; 58(1):44-50. PubMed ID: 7011783
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic combinations, side effects and interactions of antihypertensive drugs].
    Angelino PF
    Minerva Cardioangiol; 1976 Jun; 24(6):456-64. PubMed ID: 1012494
    [No Abstract]   [Full Text] [Related]  

  • 9. [Spironolactones in the treatment of essential arterial hypertension: analysis of the results obtained in 306 patients].
    Cagli V; Marquez JR; Sanguigni D
    Boll Soc Ital Cardiol; 1978; 23(10):1749-56. PubMed ID: 261838
    [No Abstract]   [Full Text] [Related]  

  • 10. [Spironolactone-thiazides-reserpine. Antihypertensive effect in essential arterial hypertension].
    de los Rios JC; Ortíz Feijoo J; Otero Cagide F
    Prensa Med Mex; 1976; 41(7-8):210-4. PubMed ID: 796845
    [No Abstract]   [Full Text] [Related]  

  • 11. Spironolactone for hypertension.
    Batterink J; Stabler SN; Tejani AM; Fowkes CT
    Cochrane Database Syst Rev; 2010 Aug; (8):CD008169. PubMed ID: 20687095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)].
    Klump F; Braun B; Klaus D; Lemke R; Zehner J; Zöfel P
    Dtsch Med Wochenschr; 1975 Mar; 100(12):577-84. PubMed ID: 1168122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of benign essential hypertension with an association of spironolactone and thiabutazide: an open multicenter study in general practice (author's transl)].
    Rhomberg F; Leya A
    Schweiz Rundsch Med Prax; 1981 Dec; 70(50):2269-78. PubMed ID: 7031639
    [No Abstract]   [Full Text] [Related]  

  • 15. Eplerenone: a review of its use in essential hypertension.
    Croom KF; Perry CM
    Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent onset severe hypertension requiring multiple antihypertensive medications.
    Diamond JA
    Am J Hypertens; 2001 Oct; 14(10):1073. PubMed ID: 11710788
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of spironolactone on blood pressure in subjects with resistant hypertension.
    Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Hypertension; 2007 Apr; 49(4):839-45. PubMed ID: 17309946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess.
    Beevers DG; Brown JJ; Ferriss JB; Fraser R; Lever AF; Robertson JI
    Am Heart J; 1973 Sep; 86(3):404-14. PubMed ID: 4592546
    [No Abstract]   [Full Text] [Related]  

  • 20. Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension.
    Rossi GP; Maiolino G
    Hypertens Res; 2014 Dec; 37(12):1029-31. PubMed ID: 25231253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.